Alzheimer's disease and retinal neurodegeneration

Current Alzheimer Research

Volumn 7, Issue 1, 2010, Pages 3-14

  Guo, L ^a   Duggan, J ^a   Cordeiro, M F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

A deposition; Age related macular degeneration; Alzheimer's disease; DARC; Glaucoma; Real time imaging technology; Retinal neurodegeneration; Tau pathology

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EYE DISEASE; GLAUCOMA; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; NERVE DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUPIL; RETINA BLOOD FLOW; RETINA DEGENERATION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NERVE CELL; REVIEW; VISUAL DISORDER;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; RETINAL DEGENERATION; TAU PROTEINS;

EID: 77949692461     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510790274491     Document Type: Review

References (156)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 368: 387-403 (2006).
2. The 2nd Alzheimer's Association International Conference on Prevention of Dementia in Washington DC. Newest Estmate of Worldwide Prevalance of Alzheimer's Disease = 26.6 Million. (2006).
3. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 35: 1219-1223 (2007).
4. Sorrentino G, Bonavita V. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. Neurol Sci 28: 63-71 (2007).
5. Moller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 248: 111-122 (1998).
6. Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 59: 673-681 (2006).
7. Davatzikos C, Resnick SM, Wu X, Parmpi P, Clark CM. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. NeuroImage 41(4): 1199-1205 (2008).
8. Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, et al. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J Cereb Blood Flow Metab 11: 323-330 (1991).
9. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, SavitchevaI, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856-2866 (2006).
10. Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. J Nutr Health Aging 12: 61S-65S (2008).
11. Bouwman FH, Schoonenboom NS, Verwey NA, van Elk EJ, Kok A, Blankenstein MA, et al. CSF biomarker levels in early and late onset al.zheimer's disease. Neurobiol Aging (2008) [Epub ahead of print].
12. Diniz BS, Pinto JA, Jr, Forlenza OV. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry 1-11 9(3): 172-182 (2007).
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
14. Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 47: 564-569 (1999).
15. Guo L, Salt TE, Maass A, Luong V, Moss SE, Fitzke FW, et al. Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo. Invest Ophthalmol Vis Sci 47: 626-633 (2006).
16. Miller N, Drachman DA. The optic nerve: a window into diseases of the brain? Neurology 67: 1742-1743 (2006).
17. Cordeiro MF, Guo L, Luong V, Harding G, Wang W, Jones HE, et al. Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci USA 101: 13352-13356 (2004).
18. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 104: 13444-13449 (2007).
19. Ning A, Cui JZ, To E, Hsiao Ashe K, Matsubara JA. Amyloid Beta Deposits Lead to Retinal Degeneration in a Mouse Model of Alzheimer Disease. Invest Ophthalmol Vis Sci 49(11): 5136-5143 (2008).
20. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 420: 97-99 (2007).
21. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 48: 2285-2289 (2007).
22. Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 26: 18-24 (2006).
23. Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer's disease. Semin Ophthalmol 18: 50-57 (2003).
24. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 112: 1860-1867 (2001).
25. Shimazawa M, Inokuchi Y, Okuno T, Nakajima Y, Sakaguchi G, Kato A, et al. Reduced retinal function in amyloid precursor protein-over-expressing transgenic mice via attenuating glutamate-N-methyl-d-aspartate receptor signaling. J Neurochem 107: 279-290 (2008).
26. Livingstone M, Hubel D. Segregation of form, color, movement, and depth: anatomy, physiology, and perception. Science (New York) 240: 740-749 (1988).
27. Hendry SH, Reid RC. The koniocellular pathway in primate vision. Annu Rev Neurosci 23: 127-153 (2000).
28. Selemon LD, Begovic A. Stereologic analysis of the lateral geniculate nucleus of the thalamus in normal and schizophrenic subjects. Psychiatr Res 151: 1-10 (2007).
29. Gupta N, Yucel YH. Glaucoma as a neurodegenerative disease. Curr Opin Ophthalmol 18: 110-114 (2007).
30. Gupta N, Yucel YH. Should we treat the brain in glaucoma? Can J Ophthalmol 42: 409-413 (2007).
31. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol 104: 113-120 (1987).
32. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 34: 31-43 (1989).
33. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 21: 709-728 (2003).
34. Cronin-Golomb A, Corkin S, Rizzo JF, Cohen J, Growdon JH, Banks KS. Visual dysfunction in Alzheimer's disease: relation to normal aging. Ann Neurol 29: 41-52 (1991).
35. Mendez MF, Cherrier MM, Meadows RS. Depth perception in Alzheimer's disease. Percept Mot Skills 83: 987-995 (1996).
36. Lee AG, Martin CO. Neuro-ophthalmic findings in the visual variant of Alzheimer's disease. Ophthalmology 111: 376-380; discussion 380-371 (2004).
37. Cronin-Golomb A. Vision in Alzheimer's disease. Gerontologist 35: 370-376 (1995).
38. Gilmore GC, Whitehouse PJ. Contrast sensitivity in Alzheimer's disease: a 1-year longitudinal analysis. Optomist Vis Sci 72: 83-91 (1995).
39. Hutton JT, Morris JL, Elias JW, Poston JN. Contrast sensitivity dysfunction in Alzheimer's disease. Neurology 43: 2328-2330 (1993).
40. Lewis DA, Campbell MJ, Terry RD, Morrison JH. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices. J Neurosci 7: 1799-1808 (1987).
41. Hof PR, Morrison JH. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J Comp Neurol 301: 55-64 (1990).
42. Rizzo JF, 3rd, Cronin-Golomb A, Growdon JH, Corkin S, Rosen TJ, Sandberg MA, et al. Retinocalcarine function in Alzheimer's disease. A clinical and electrophysiological study. Arch Neurol 49: 93-101 (1992).
43. Morrison JH, Hof PR, Bouras C. An anatomic substrate for visual disconnection in Alzheimer's disease. Ann NY Acad Sci 640: 36-43 (1991).
44. Mountjoy CQ, Roth M, Evans NJ, Evans HM. Cortical neuronal counts in normal elderly controls and demented patients. Neurobiol Aging 4: 1-11 (1983).
45. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 315: 485-487 (1986).
46. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology 97: 9-17 (1990).
47. Livingstone MS, Hubel DH. Psychophysical evidence for separate channels for the perception of form, color, movement, and depth. J Neurosci 7: 3416-3468 (1987).
48. Scinto LF, Daffner KR, Dressler D, Ransil BI, Rentz D, Weintraub S, et al. A potential noninvasive neurobiological test for Alzheimer's disease. Science (New York, NY) 266: 1051-1054 (1994).
49. Gomez-Tortosa E, del Barrio A, Jimenez-Alfaro I. Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. Acta Neurol Scand 94: 104-109 (1996).
50. Higuchi S, Matsushita S, Hasegawa Y, Muramatsu T, Arai H. Pupillary response to tropicamide in Japanese patients with alcoholic dementia, Alzheimer's disease, and vascular dementia. Exp Neurol 144: 199-201 (1997).
51. Iijima A, Haida M, Ishikawa N, Ueno A, Minamitani H, Shinohara Y. Re-evaluation of tropicamide in the pupillary response test for Alzheimer's disease. Neurobiol Aging 24: 789-796 (2003).
52. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (New York, NY) 261: 921-923 (1993).
53. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342: 697-699 (1993).
54. Scinto LF. ApoE allelic variability influences pupil response to cholinergic challenge and cognitive impairment. Genes Brain Behav 6: 209-215 (2007).
55. Scinto LF. Pupillary cholinergic hypersensitivity predicts cognitive decline in community dwelling elders. Neurobiol Aging 29: 222-230 (2008).
56. Hess EH, Polt JM. Pupil Size in Relation to Mental Activity during Simple Problem-Solving. Science (New York, NY) 143: 1190-1192 (1964).
57. Fotiou DF, Brozou CG, Haidich AB, Tsiptsios D, Nakou M, Kabitsi A, et al. Pupil reaction to light in Alzheimer's disease: evaluation of pupil size changes and mobility. Aging Clin Exp Res 19: 364-371 (2007).
58. Fotiou F, Fountoulakis KN, Tsolaki M, Goulas A, Palikaras A. Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report. Int J Psychophysiol 37: 111-120 (2000).
59. Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res 501: 364-372 (1989).
60. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging 17: 385-395 (1996).
61. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 17: 377-384 (1996).
62. Curcio CA, Drucker DN. Retinal ganglion cells in Alzheimer's disease and aging. Ann Neurol 33: 248-257 (1993).
63. Davies DC, McCoubrie P, McDonald B, Jobst KA. Myelinated axon number in the optic nerve is unaffected by Alzheimer's disease. Br J Ophthalmol 79: 596-600 (1995).
64. Loffler KU, Edward DP, Tso MO. Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci 36: 24-31 (1995).
65. Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S. {beta}-Amyloid Deposition and Functional Impairment in the Retina of the APPswe/PS1{Delta}E9 Transgenic Mouse Model of Alzheimer's Disease. Invest Ophthalmol Vis Sci (2008).
66. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. Science (New York, NY) 254: 1178-1181. (1991).
67. Schuman JS, Pedut-Kloizman T, Pakter H, Wang N, Guedes V, Huang L, et al. Optical coherence tomography and histologic measurements of nerve fiber layer thickness in normal and glaucomatous monkey eyes. Invest Ophthalmol Vis Sci 48: 3645-3654 (2007).
68. Soliman MA, Van Den Berg TJ, Ismaeil AA, De Jong LA, De Smet MD. Retinal nerve fiber layer analysis: relationship between optical coherence tomography and red-free photography. Am J Ophthalmol 133: 187-195 (2002).
69. Drexler W. Ultrahigh-resolution optical coherence tomography. J Biomed Opt 9: 47-74 (2004).
70. Drexler W, Morgner U, Ghanta RK, Kartner FX, Schuman JS, Fujimoto JG. Ultrahigh-resolution ophthalmic optical coherence tomography. Nat Med 7: 502-507 (2001).
71. Truong SN, Alam S, Zawadzki RJ, Choi SS, Telander DG, Park SS, et al. High resolution Fourier-domain optical coherence tomography of retinal angiomatous proliferation. Retina (Philadelphia), PA 27: 915-925 (2007).
72. Huber R, Adler DC, Srinivasan VJ, Fujimoto JG. Fourier domain mode locking at 1050 nm for ultra-high-speed optical coherence tomography of the human retina at 236,000 axial scans per second. Opt Lett 32: 2049-2051 (2007).
73. Bizheva K, Pflug R, Hermann B, Povazay B, Sattmann H, Qiu P, et al. Optophysiology: depth-resolved probing of retinal physiology with functional ultrahigh-resolution optical coherence tomography. Proc Natl Acad Sci USA 103: 5066-5071 (2006).
74. Okawa Y, Fujikado T, Miyoshi T, Sawai H, Kusaka S, Mihashi T, et al. Optical imaging to evaluate retinal activation by electrical currents using suprachoroidal-transretinal stimulation. Invest Ophthalmol Vis Sci 48: 4777-4784 (2007).
75. Wang Y, Bower BA, Izatt JA, Tan O, Huang D. In vivo total retinal blood flow measurement by Fourier domain Doppler optical coherence tomography. J Biomed Opt 12: 041215 (2007).
76. Lu CW, Lee CK, Tsai MT, Wang YM, Yang CC. Measurement of the hemoglobin oxygen saturation level with spectroscopic spectral-domain optical coherence tomography. Opt Lett 33: 416-418 (2008).
77. Kagemann L, Wollstein G, Wojtkowski M, Ishikawa H, Townsend KA, Gabriele ML, et al. Spectral oximetry assessed with high-speed ultra-high-resolution optical coherence tomography. J Biomed Opt 12: 041212 (2007).
78. Valenti DA. Neuroimaging of retinal nerve fiber layer in AD using optical coherence tomography. Neurology 69: 1060 (2007).
79. Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer's type. Neurology 45: 68-74 (1995).
80. Katz B, Rimmer S, Iragui V, Katzman R. Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration? Ann Neurol 26: 221-225 (1989).
81. Hollander H, Bisti S, Maffei L, Hebel R. Electroretinographic responses and retrograde changes of retinal morphology after intracranial optic nerve section. A quantitative analysis in the cat. Exp Brain Res Experimentelle Hirnforschung 55: 483-493 (1984).
82. Trick GL, Barris MC, Bickler-Bluth M. Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. Ann Neurol 26: 226-231 (1989).
83. Zeimer R, Asrani S, Zou S, Quigley H, Jampel H. Quantitative detection of glaucomatous damage at the posterior pole by retinal thickness mapping. A pilot study. Ophthalmology 105: 224-231 (1998).
84. Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 67: 1852-1854 (2006).
85. Tsai CS, Ritch R, Schwartz B, Lee SS, Miller NR, Chi T, et al. Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch Ophthalmol 109: 199-204 (1991).
86. Hedges TR, 3rd, Perez GR, Speigelman D, Barbas NR, Peli E, Yardley CJ. Retinal nerve fiber layer abnormalities in Alzheimer's disease. Acta Ophthalmol Scand 74: 271-275 (1996).
87. de la Torre JC. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener Dis 5: 126-132 (2008).
88. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57: 789-794 (2005).
89. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci 46: 175-182 (2005).
90. Maass A, von Leithner PL, Luong V, Guo L, Salt TE, Fitzke FW, et al. Assessment of Rat and Mouse RGC Apoptosis Imaging in Vivo with Different Scanning Laser Ophthalmoscopes. Curr Eye Res 32: 851-861 (2007).
91. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 361: 1258-1265 (2003).
92. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866 (1999).
93. Moncaster JA, Moir RD, Mocofanescu A, Burton M, Fu L, Xu W, et al. In vivo early detection of alzheimer's disease-linked ab peptide accumulation in the lens using quasi-elastic light scattering ARVO 4080) (2008).
94. Melov S, Wolf N, Strozyk D, Doctrow SR, Bush AI. Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radic Biol Med 38: 258-261 (2005).
95. Frederikse PH, Ren XO. Lens defects and age-related fiber cell degeneration in a mouse model of increased AbetaPP gene dosage in Down syndrome. Am J Pathol 161: 1985-1990 (2002).
96. Lott IT. Down's syndrome, aging, and Alzheimer's disease: a clinical review. Anne NY Acad Sci 396: 15-27 (1982).
97. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2: 93-95 (1996).
98. da Cunha RP, Moreira JB. Ocular findings in Down's syndrome. Am J Ophthalmol 122: 236-244 (1996).
99. Frederikse PH, Garland D, Zigler JS, Jr, Piatigorsky J. Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem 271: 10169-10174 (1996).
100. Li G, Percontino L, Sun Q, Qazi AS, Frederikse PH. Beta-amyloid secretases and beta-amloid degrading enzyme expression in lens. Mol Vis 9: 179-183 (2003).
101. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90: 262-267 (2006).
102. Oliver JE, Hattenhauer MG, Herman D, Hodge DO, Kennedy R, Fang-Yen M, et al. Blindness and glaucoma: a comparison of patients progressing to blindness from glaucoma with patients maintaining vision. Am J Ophthalmol 133: 764-772 (2002).
103. Collaborative Normal-Tension Glaucoma Study Group T. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 126: 487-497 (1998).
104. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol 47: 165-168 (2002).
105. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol 133: 135-137 (2002).
106. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K, et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci 246: 79-83 (2006).
107. Bayer AU, Ferrari F. Severe progression of glaucomatous optic neuropathy in patients with Alzheimer's disease. Eye 16: 209-212 (2002).
108. Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol 49: 106-108 (2005).
109. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613 (2003).
110. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60: 652-656 (2003).
111. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38: 643-648 (1995).
112. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 43: 1077-1087 (2002).
113. Goldblum D, Kipfer-Kauer A, Sarra GM, Wolf S, Frueh BE. Distribution of Amyloid Precursor Protein and Amyloid-{beta} Immunoreactivity in DBA/2J Glaucomatous Mouse Retinas. Invest Ophthalmol Vis Sci 48: 5085-5090 (2007).
114. Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, et al. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nat Med 6: 397-404 (2000).
115. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97: 395-406 (1999).
116. Gupta N, Fong J, Ang LC, Yucel YH. Retinal tau pathology in human glaucomas. Can J Ophthalmol 43: 53-60 (2008).
117. Crawford ML, Harwerth RS, Smith EL, 3rd, Mills S, Ewing B. Experimental glaucoma in primates: changes in cytochrome oxidase blobs in V1 cortex. Invest Ophthalmol Vis Sci 42: 358-364 (2001).
118. Crawford ML, Harwerth RS, Smith EL, 3rd, Shen F, Carter-Dawson L. Glaucoma in primates: cytochrome oxidase reactivity in parvo- and magnocellular pathways. Invest Ophthalmol Vis Sci 41: 1791-1802 (2000).
119. Yucel YH, Zhang Q, Gupta N, Kaufman PL, Weinreb RN. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol 118: 378-384 (2000).
120. Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Atrophy of relay neurons in magno- and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Ophthalmol Vis Sci 42: 3216-3222 (2001).
121. Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retinal Eye Res 22: 465-481 (2003).
122. Duncan RO, Sample PA, Weinreb RN, Bowd C, Zangwill LM. Retinotopic organization of primary visual cortex in glaucoma: a method for comparing cortical function with damage to the optic disk. Invest Ophthalmol Vis Sci 48: 733-744 (2007).
123. Gupta N, Ly T, Zhang Q, Kaufman PL, Weinreb RN, Yucel YH. Chronic ocular hypertension induces dendrite pathology in the lateral geniculate nucleus of the brain. Exp Eye Res 84: 176-184 (2007).
124. Lam DY, Kaufman PL, Gabelt BT, To EC, Matsubara JA. Neurochemical correlates of cortical plasticity after unilateral elevated intraocular pressure in a primate model of glaucoma. Invest Ophthalmol Vis Sci 44: 2573-2581 (2003).
125. Liu M, Georgiou A, Guo L, Salt TE, Cordeiro MF. Dendritic pathology in the superior colliculus in a rat model of experimental glaucoma. ARVO Abstract 5199 (2008).
126. Gupta N, Ang LC, Noel de Tilly L, Bidaisee L, Yucel YH. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol 90: 674-678 (2006).
127. Chaturvedi N, Hedley-Whyte ET, Dreyer EB. Lateral geniculate nucleus in glaucoma. Am J Ophthalmol 116: 182-188 (1993).
128. Sugiyama T, Utsunomiya K, Ota H, Ogura Y, Narabayashi I, Ikeda T. Comparative study of cerebral blood flow in patients with normal-tension glaucoma and control subjects. Am J Ophthalmol 141: 394-396 (2006).
129. Cedazo-Minguez A. Apolipoprotein E, Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med 11: 1227-1238 (2007).
130. Vickers JC, Craig JE, Stankovich J, McCormack GH, West AK, Dickinson JL, et al. The apolipoprotein epsilon4 gene is associated with elevated risk of normal tension glaucoma. Mol Vis 8: 389-393 (2002).
131. Mabuchi F, Tang S, Ando D, Yamakita M, Wang J, Kashiwagi K, et al. The apolipoprotein E gene polymorphism is associated with open angle glaucoma in the Japanese population. Mol Vis 11: 609-612 (2005).
132. Lake S, Liverani E, Desai M, Casson R, James B, Clark A, et al. Normal tension glaucoma is not associated with the common apolipoprotein E gene polymorphisms. Br J Ophthalmol 88: 491-493 (2004).
133. Ressiniotis T, Griffiths PG, Birch M, Keers S, Chinnery PF. The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma. Arch Ophthalmol 122: 258-261 (2004).
134. McKinnon SJ. Glaucoma: ocular Alzheimer's disease? Front Biosci 8: s1140-1156 (2003).
135. Wostyn P. Can chronic increased intracranial pressure or exposure to repetitive intermittent intracranial pressure elevations raise your risk for Alzheimer's disease? Med Hypotheses 62: 925-930 (2004).
136. Wostyn P, Audenaert K, De Deyn PP. Alzheimer's disease-related changes in diseases characterized by elevation of intracranial or intraocular pressure. Clin Neurol Neurosurg 110: 101-109 (2008).
137. Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Survey Ophthalmol 48: S25-37 (2003).
138. Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol 48 (Suppl 1): S25-37 (2003).
139. Yin H, Chen L, Chen X, Liu X. Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. Med Hypotheses 71(1): 77-80 (2008).
140. Wostyn P. Normal-tension glaucoma and Alzheimer's disease: Hypothesis of a possible common underlying risk factor. Med Hypotheses 67: 1255-1256 (2006).
141. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 99: 11830-11835 (2002).
142. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78: 243-256 (2004).
143. McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and the diseases of aging. Neurobiol Aging 26 (Suppl 1): 94-97 (2005).
144. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 48: 339-345 (2008).
145. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 16: 516-527 (1989).
146. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89: 10016-10020 (1992).
147. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol 123: 199-206 (1997).
148. Souied EH, Benlian P, Amouyel P, Feingold J, Lagarde JP, Munnich A, et al. The epsilon4 allele of the apolipoprotein E gene as a potential protective factor for exudative age-related macular degeneration. Am J Ophthalmol 125: 353-359 (1998).
149. Russ MO, Cleff U, Lanfermann H, Schalnus R, Enzensberger W, Kleinschmidt A. Functional magnetic resonance imaging in acute unilateral optic neuritis. J Neuroimaging 12: 339-350 (2002).
150. Klaver CC, Kliffen M, van Duijn CM, Hofman A, Cruts M, Grobbee DE, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 63: 200-206 (1998).
151. Baird PN, Guida E, Chu DT, Vu HT, Guymer RH. The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 45: 1311-1315 (2004).
152. Takacs-Vellai K, Vellai T, Puoti A, Passannante M, Wicky C, Streit A, et al. Inactivation of the autophagy gene bec-1 triggers apoptotic cell death in C. elegans. Curr Biol 15: 1513-1517 (2005).
153. Malek G, Johnson LV, Mace BE, Saloupis P, Schmechel DE, Rickman DW, et al. Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci USA 102: 11900-11905 (2005).
154. Dithmar S, Holz FG, Burk RO, Rohrschneider K, Volcker HE. [Confocal scanning laser indocyanine green angiography with the Heidelberg retinal angiograph]. Klin Monatsbl Augenheilkd 207: 11-16 (1995).
155. Geylis V, Steinitz M. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 5: 33-39 (2006).
156. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277: 32046-32053 (2002).